Therefore, therapies based on multiple daily injections (MDI), the combination of slow-acting insulin for basal coverage and rapid-acting insulin at mealtimes to control postprandial blood glucose levels, are still the most widespread treatments for people suffering from type 1 diabetes [16]. This evidence concerns the gene INS and type 1 diabetes mellitus.